GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status

The FDA maintains a Drug Shortage List that determines whether compounded versions of brand-name drugs are legally permissible. When an FDA-approved drug is in shortage, compounding pharmacies may legally prepare compounded versions under 21 CFR 503.226 (outsourcing facility compounding). When shortage status ends, compounding authority reverts to state pharmacy boards under 503.A (traditional compounding), which is more restrictive.

As of late 2026, semaglutide and tirzepatide shortage status has fluctuated. You must verify current status directly on the FDA Drug Shortage List (fda.gov/drugs/drug-shortages) before sourcing. Compounding pharmacies should provide documentation of shortage status at the time of dispensing. If a pharmacy sources compounded GLP-1 without active shortage authority, the product is technically unapproved and carries enforcement risk for both the pharmacy and the prescriber dispensing it.

Key distinction: outsourcing facility compounding (503.226) requires FDA registration and inspection; traditional compounding (503.A) does not but is limited to individual patient prescriptions and cannot be marketed in bulk.

GLP-1 dispensing in aesthetic practices hinges on prescriber licensure and state scope-of-practice law. A licensed physician, nurse practitioner (NP), or physician assistant (PA) must issue the prescription; the degree of supervision varies by state.

Physician-owned practices: Straightforward—the owner or employed physician prescribes and supervises. No additional delegation required.

Nurse-injector or aesthetician-led practices: More complex. If an NP or PA owns the practice, they can prescribe directly. If a non-prescriber (aesthetician, RN without NP credential) owns the practice, they must have a supervising physician on contract or employed. State boards differ on whether supervision must be on-site, remote, or chart-review-only. Some states (e.g., Florida, Texas) allow remote supervision; others require presence. Verify your state's Nurse Practice Act and Board of Medicine regulations.

Corporate Practice of Medicine (CPM) doctrine: Several states (California, Texas, Florida) prohibit non-physicians from owning medical practices. If you operate in a CPM state and are not a physician, you cannot own a practice that prescribes GLP-1. MSO (management services organization) structures can work around this, but require careful legal setup. Consult your state's medical board and a healthcare attorney.

Compounding pharmacies are the primary legal source for GLP-1 in aesthetic practices. They prepare custom doses and formulations (e.g., 2.4 mg/0.4 mL pens, multi-dose vials) from bulk API (active pharmaceutical ingredient). Verify the pharmacy is state-licensed and, if compounding under 503.226, FDA-registered as an outsourcing facility.

Key questions to ask your compounding pharmacy:

• What is the current FDA shortage status for semaglutide/tirzepatide? (Request documentation.)
• Are you state-licensed and, if applicable, FDA-registered as an outsourcing facility?
• What is your quality assurance protocol (sterility testing, potency verification)?
• Do you provide a Certificate of Analysis (CoA) for each batch?
• What is your liability insurance coverage?

Wholesale diversion (purchasing brand-name Ozempic or Mounjaro through gray-market wholesalers or international channels) is illegal and exposes you to DEA and state pharmacy board enforcement, product liability, and criminal charges. Do not source this way.

Direct-to-consumer compounding services (online platforms offering pre-filled pens or vials shipped to patients) blur the line between pharmacy and practice. If you are dispensing these to your patients, ensure the pharmacy is licensed in your state and compliant with state pharmacy board regulations on mail delivery and patient counseling.

State pharmacy and medical boards have begun enforcement actions against practices offering GLP-1 without proper prescriber licensure, supervision, or sourcing documentation. Enforcement typically targets:

• Unlicensed prescribing: Aestheticians or RNs without NP/PA credentials issuing GLP-1 prescriptions.
• Inadequate supervision: NP/PA prescribing without documented physician oversight in states requiring it.
• Unlicensed pharmacy operations: Practices compounding or dispensing GLP-1 without pharmacy licensure.
• Unapproved sourcing: Dispensing compounded GLP-1 when no shortage exists, or sourcing diverted brand-name product.

Penalties include cease-and-desist orders, license suspension or revocation, fines, and criminal referral. Medical boards also scrutinize off-label prescribing (e.g., GLP-1 for cosmetic body contouring without diabetes or obesity diagnosis) and may require documented informed consent and medical necessity.

To mitigate risk: maintain clear prescriber credentials and supervision documentation, source only from state-licensed compounding pharmacies with FDA registration (if applicable), keep Certificates of Analysis on file, document patient informed consent, and ensure your prescriber has a legitimate medical reason for each prescription. Consider consulting a healthcare compliance attorney in your state.

The FDA and FTC have issued warnings about unlicensed GLP-1 dispensing, particularly through telehealth platforms and direct-to-consumer services. The FDA has sent warning letters to compounding pharmacies and practices offering GLP-1 without proper authority, and the FTC has targeted deceptive marketing claims (e.g., "medically supervised weight loss" without actual physician oversight).

If your practice uses telehealth to prescribe GLP-1, ensure:

• The prescriber is licensed in the patient's state (not just your state).
• A genuine physician-patient relationship exists (not a one-off video call).
• Prescriptions are issued for a legitimate medical indication, not cosmetic use.
• Records are maintained and available for audit.

DEA scrutiny is lower for GLP-1 (not a controlled substance), but if you are diverting brand-name product or operating an unlicensed pharmacy, federal charges are possible.

Monitor the FDA Drug Shortage List and state board enforcement actions (published on your state's medical and pharmacy board websites) for changes in policy or enforcement priorities. Subscribe to alerts from your state board and your compounding pharmacy.

Before offering GLP-1 in your practice:

• Verify prescriber credentials: Confirm your prescriber (you, an employed physician, or contracted NP/PA) is licensed and in good standing in your state.
• Check state supervision law: Consult your state's medical board website or a healthcare attorney on supervision requirements for NP/PA prescribing.
• Vet your compounding pharmacy: Request state license, FDA registration (if applicable), CoA samples, and liability insurance certificate. Verify they document shortage status.
• Document sourcing: Keep all pharmacy invoices, CoAs, and shortage-status documentation on file.
• Obtain informed consent: Use a written consent form disclosing off-label use (if applicable), risks, and that the product is compounded (not FDA-approved).
• Maintain prescriber records: Document the medical indication and prescriber rationale for each patient.
• Monitor regulatory changes: Check the FDA Drug Shortage List quarterly and subscribe to your state board's enforcement alerts.
• Consult legal counsel: Have a healthcare attorney review your GLP-1 program, especially if you operate across multiple states or use telehealth.

Non-compliance can result in license loss, fines, and civil liability. Compliance is the cost of operating in this space.